Navigation Links
Inverness Medical Innovations to Present at the J.P. Morgan Healthcare Conference on January 12, 2010
Date:12/30/2009

WALTHAM, Mass., Dec. 30 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (NYSE: IMA), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, announced today that it will attend the J.P. Morgan Healthcare Conference being held January 11 through 14, 2010 at the Westin St. Francis Hotel in San Francisco. Ron Zwanziger, Chief Executive Officer, and Jon Russell, Vice President, Finance, will attend. Mr. Zwanziger's presentation is scheduled for Tuesday, January 12, 2010 at 2:00 p.m. PT (5:00 p.m. ET), and will be made available to the public through a webcast accessible via http://metameetings.com/webcasts/jpmorgan/healthcare10/directlink?ticker=IMA, as well as through the company's website at http://www.invmed.com/investors.cfm. A replay of the webcast will be available via the links above for approximately 30 days from the date of the webcast. During his presentation, Mr. Zwanziger or Mr. Russell may discuss and answer questions concerning business and financial developments and trends. Their responses to questions, as well as other matters discussed during the webcast, may contain or constitute information that has not been disclosed previously.

Prior to the conference the Company will also be posting an updated investor presentation on its website at www.invmed.com/investors.cfm .

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.

SOURCE Inverness Medical Innovations, Inc.


'/>"/>
SOURCE Inverness Medical Innovations, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
2. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
3. Inverness Medical Innovations Receives USDA Licensure of the BinaxNOW(R) Avian Influenza Virus Type A Antigen Test Kit
4. Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General
5. Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimers Disease
6. Inverness Medical Innovations Announces Third Quarter 2009 Results
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. Globus Medical Raises $110 Million in Series E Financing Round
11. Quark Pharmaceuticals Appoints New Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/13/2017)... 2017   OrthoAtlanta has been named the official ... Committee (AFHC) for the 2018 College Football Playoff (CFP) National ... Mercedes-Benz Stadium in Atlanta, Georgia . OrthoAtlanta ... In" campaign, participating in many activities leading up to, and ... ...
(Date:9/12/2017)... 2017  ValGenesis Inc., the global leader in ... to announce the appointment of Dr. Ajaz ... of Directors and Chairman of Advisory Board beginning ... companies to manage their entire validation lifecycle process ... this process. Furthermore, ValGenesis VLMS enables rigorous compliance, ...
(Date:9/9/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... lasmiditan, an investigational, oral, first-in-class molecule for the acute ... to placebo in the Phase 3 SPARTAN study. Detailed ... of the International Headache Society (IHC) in ... demonstrate lasmiditan,s potential to reduce pain and provide freedom ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... Recognising that in ... from Leany Greeny delivers positive results in just three weeks. Setting the groundwork ... the metabolism. Fitting seamlessly into hectic work and family schedules, participants can lose ...
(Date:9/20/2017)... ... ... “Finn Mouseson”: follows the exciting story of a mouse as the need for adventure ... journey that will show that friends are to be gathered but home is always ... Melody Gersonde-Mickelson, who has earned a bachelor’s degree in Fine Arts from the University ...
(Date:9/20/2017)... ... 2017 , ... “Psalms of Humidity”: is a fascinating depiction of daily struggles ... one step closer to God. “Psalms of Humidity” is the creation of published author, ... made within his life are the very same things that have shaped him into ...
(Date:9/20/2017)... ... 20, 2017 , ... “They Sang At Her Funeral”: a tale of murder ... the skeletons in their closets. “They Sang At Her Funeral” is the creation of ... and married with five children and twelve grandchildren. Before becoming a writer, Annalise had ...
(Date:9/19/2017)... ... September 19, 2017 , ... Only a few physicians were ... Brevard’s own Ross A. Clevens, MD, FACS . The founder and medical director ... and Reconstructive Surgeon who trained at Yale, Harvard and the University of Michigan. He ...
Breaking Medicine News(10 mins):